Revium Rx (RVRC) Debt to Equity (2024 - 2025)

Revium Rx's (RVRC) quarterly Debt to Equity came in at $0.08 in Q4 2025, up 658.85% year-on-year from $0.01 in Q4 2024, and up 658.85% quarter-over-quarter from $0.01 in Q4 2024.

Revium Rx (RVRC) Debt to Equity (2024 - 2025) Analysis & Trends

Revium Rx has disclosed Debt to Equity across 2 years of filings, most recently posting $0.08 for Q4 2025.

  • Debt to Equity for Q4 2025 came in at $0.08, up 658.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.08 (up 658.85% YoY), and the FY2025 annual result was $0.08, up 658.85% from the prior year.
  • Debt to Equity came in at $0.08 for Q4 2025 at Revium Rx, up from $0.01 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.08 in Q4 2025 to a low of $0.01 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Veeva Systems 24.83 Bn 17.52 Bn 662.02 Mn -
2 BrightSpring Health Services 13.57 Bn 12.69 Bn 482.22 Mn 1.26
3 Healthequity 7.20 Bn 6.93 Bn 256.31 Mn 0.46
4 Hinge Health 5.42 Bn 5.11 Bn 154.23 Mn -
5 10x Genomics 4.46 Bn 3.92 Bn 106.18 Mn -
6 Doximity 3.81 Bn 3.06 Bn 125.97 Mn -
7 Waystar Holding 3.52 Bn 3.36 Bn 268.04 Mn 0.37
8 Privia Health 2.94 Bn 2.57 Bn 595.71 Mn -
9 Omnicell 1.76 Bn 1.59 Bn 140.36 Mn -
10 Revium Rx - - - 0.08

Historic Data

Download Data
DateValue
Dec 31, 2025 0.08
Dec 31, 2024 0.01